New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis

This press release features multimedia.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, April 25, 2019
Information
Tags: 
Health, Biotechnology, Pharmaceutical, Organ systems, Medicine, Medical specialties, Monoclonal antibodies, Autoimmune diseases, Immunosuppressants, Psoriasis, RTT, Brodalumab, Ustekinumab, Pasi, Guselkumab
Geotags: 
Europe, CENTRAL AMERICA, South America, Canada, DENMARK
⚠generated by AI ↴
Summary
Key Points: 
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20190425005072/en/
    The post-hoc analysis of the AMAGINE-2 and AMAGINE-3 studies which included 3,712 people with moderate-to-severe psoriasis shows that 90% of patients treated with brodalumab who achieved PASI 100 also experienced sustained PASI 100.
  • In the same analysis, only 77% of patients treated with ustekinumab who achieved PASI 100 also experienced sustained PASI 100.
  • These results show that brodalumab can offer more patients a longer, more sustained period of complete skin clearance than ustekinumab.


LEO Pharma A/S, a global leader in medical dermatology, today announced
that new data presented this week at the 6th Congress of the Skin
Inflammation and Psoriasis International Network (SPIN) in Paris
demonstrate that more patients with moderate-to-severe psoriasis who
received treatment with brodalumab maintained a PASI (Psoriasis Area
Severity Index) 100 score for longer than those who were treated with
ustekinumab over 52 weeks.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190425005072/en/

The post-hoc analysis of the AMAGINE-2 and AMAGINE-3 studies – which
included 3,712 people with moderate-to-severe psoriasis – shows that 90%
of patients treated with brodalumab who achieved PASI 100 also
experienced sustained PASI 100. In the same analysis, only 77% of
patients treated with ustekinumab who achieved PASI 100 also experienced
sustained PASI 100. Study authors measured ‘sustained PASI 100’ as the
time to inadequate response, based on a static physician’s global
assessment (sPGA) of ≥3 or persistent values of 2 over at least a 4-week
period at or after week 16.1

Because the sub-populations of patients treated with brodalumab and
ustekinumab in these studies had different baseline characteristics, the
study authors did not apply statistical comparisons.

“Newer treatments for moderate-to-severe psoriasis have made it
possible for patients to completely clear their skin, but the disease
fluctuates over time, so we wanted to explore how fast and for how long
patients can count on having complete skin clearance,” said Professor
Lluís Puig, Director, Department of Dermatology, Hospital de la Santa
Creu i Sant Pau, Universitat Autònoma de Barcelona. “These results show
that brodalumab can offer more patients a longer, more sustained period
of complete skin clearance than ustekinumab. That difference can have a
big impact on patients’ quality of life.”

Copyright: 
Copyright Business Wire 2019